- Home
- PBA vs WAT Comparison
PBA vs WAT Comparison
Compare PBA & WAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBA
- WAT
- Stock Information
- Founded
- PBA 1997
- WAT 1958
- Country
- PBA Canada
- WAT United States
- Employees
- PBA N/A
- WAT N/A
- Industry
- PBA Oil & Gas Production
- WAT Biotechnology: Laboratory Analytical Instruments
- Sector
- PBA Energy
- WAT Industrials
- Exchange
- PBA Nasdaq
- WAT Nasdaq
- Market Cap
- PBA 24.0B
- WAT 22.5B
- IPO Year
- PBA N/A
- WAT 1995
- Fundamental
- Price
- PBA $38.37
- WAT $378.38
- Analyst Decision
- PBA Buy
- WAT Hold
- Analyst Count
- PBA 1
- WAT 12
- Target Price
- PBA $57.00
- WAT $374.75
- AVG Volume (30 Days)
- PBA 1.3M
- WAT 517.0K
- Earning Date
- PBA 11-05-2024
- WAT 02-04-2025
- Dividend Yield
- PBA 5.19%
- WAT N/A
- EPS Growth
- PBA 51.43
- WAT N/A
- EPS
- PBA 2.43
- WAT 10.48
- Revenue
- PBA $7,305,229,650.00
- WAT $2,905,147,000.00
- Revenue This Year
- PBA N/A
- WAT $0.53
- Revenue Next Year
- PBA $15.54
- WAT $5.59
- P/E Ratio
- PBA $15.81
- WAT $36.11
- Revenue Growth
- PBA 37.18
- WAT N/A
- 52 Week Low
- PBA $32.80
- WAT $279.24
- 52 Week High
- PBA $43.44
- WAT $397.02
- Technical
- Relative Strength Index (RSI)
- PBA 25.99
- WAT 50.97
- Support Level
- PBA $38.75
- WAT $380.60
- Resistance Level
- PBA $39.39
- WAT $397.02
- Average True Range (ATR)
- PBA 0.68
- WAT 9.83
- MACD
- PBA -0.28
- WAT -1.21
- Stochastic Oscillator
- PBA 2.60
- WAT 25.05
About PBA Pembina Pipeline Corp. (Canada)
Pembina Pipeline is a midstream company serving the Canadian and North American (primarily Bakken) markets with an integrated product portfolio. Its assets include pipelines and gas gathering as well as assets across fractionation, storage, and propane exports.
About WAT Waters Corporation
Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2023, Waters generated 57% from biopharmaceutical customers, 31% from industrial clients, and 12% from academic/government institutions.